Early phase clinical trial to evaluate the effectiveness and safety of
A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS)
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- BCG20-0134
What it measured
Main measures
Cumulative number of new gadolinium-enhanced (GdE) T1 weighted lesions developing while on treatment (specifically the sum of new GdE T1 lesions seen on MRI at weeks 12, 16, 20 and 24).
MRI lesions
Other measures (1)
see E.2.2 Secondary objectives
Who could take part
Relapsing MS · EDSS 0 to 5.5
Show the full criteria
Inclusion criteria
Inclusion: Patients aged ≥18 with relapsing-remitting multiple sclerosis (EDSS score 0-5.5), with evidence of disease activity defined as at least one relapse or the presence of active MRI lesion/s consistent with MS during the year prior to inclusion Exclusion: MS-related exclusion criteria:
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
General Aim:
Loading reviews and guidelines…
History
- Status changed from Ongoing to Status unknown
- Result signal changed from Ongoing to Status unknown
Started
Jul 2009